- Home
- STSS vs VIVS Comparison
STSS vs VIVS Comparison
Compare STSS & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STSS
- VIVS
- Stock Information
- Founded
- STSS 2017
- VIVS 2007
- Country
- STSS United States
- VIVS United States
- Employees
- STSS N/A
- VIVS N/A
- Industry
- STSS Medical/Dental Instruments
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STSS Health Care
- VIVS Health Care
- Exchange
- STSS Nasdaq
- VIVS Nasdaq
- Market Cap
- STSS 5.1M
- VIVS 4.7M
- IPO Year
- STSS 2022
- VIVS N/A
- Fundamental
- Price
- STSS $7.36
- VIVS $2.11
- Analyst Decision
- STSS
- VIVS
- Analyst Count
- STSS 0
- VIVS 0
- Target Price
- STSS N/A
- VIVS N/A
- AVG Volume (30 Days)
- STSS 90.2K
- VIVS 45.8K
- Earning Date
- STSS 08-13-2025
- VIVS 08-12-2025
- Dividend Yield
- STSS N/A
- VIVS N/A
- EPS Growth
- STSS N/A
- VIVS N/A
- EPS
- STSS N/A
- VIVS N/A
- Revenue
- STSS $222,722.00
- VIVS $142,000.00
- Revenue This Year
- STSS N/A
- VIVS $42.38
- Revenue Next Year
- STSS N/A
- VIVS $15.42
- P/E Ratio
- STSS N/A
- VIVS N/A
- Revenue Growth
- STSS N/A
- VIVS 94.52
- 52 Week Low
- STSS $3.36
- VIVS $1.41
- 52 Week High
- STSS $2,145.00
- VIVS $21.96
- Technical
- Relative Strength Index (RSI)
- STSS 67.00
- VIVS 63.00
- Support Level
- STSS $4.54
- VIVS $1.72
- Resistance Level
- STSS $5.95
- VIVS $1.89
- Average True Range (ATR)
- STSS 0.74
- VIVS 0.13
- MACD
- STSS 0.18
- VIVS 0.02
- Stochastic Oscillator
- STSS 96.92
- VIVS 86.96
About STSS Sharps Technology Inc.
Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes designed to eliminate potentially infectious and accidental needlestick injuries.
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.